Literature DB >> 14635026

Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure.

Anne-Geneviève Marcelin1, Constance Delaugerre, Marc Wirden, Pedro Viegas, Anne Simon, Christine Katlama, Vincent Calvez.   

Abstract

During ZDV or d4T exposure, mutations at codons 41, 67, 70, 210, 215, and 219 can be selected and were named thymidine analogue mutations (TAMs). Some previous results suggested that different TAMs patterns could exist and that the kind of TAMs pattern could influence the virological response to some nucleoside reverse transcriptase inhibitors (NRTIs). In order to get more data about the relative prevalence of these patterns, their associations with other NRTI resistance mutations and the identification of the different stages observed during the acquisition of TAMs under treatment by NRTIs, we collected 1,098 RT sequences harbouring at least one TAM from patients failing to antiretroviral regimen. Sequences were stored in a database designed specifically to allow the retrieval of sequences that met specific criteria such as the occurrence and frequency of a particular mutation, the nature and frequency of the amino acid substitution at a given codon, and/or the rate of association between resistance mutations. Two pathways of TAMs can be identified: profile #1 (T215Y mutation linked) and profile # 2 (T215F mutation linked). The frequency of selection of profile # 1 is two times higher than profile # 2. The E44D/A + V118I complex, 69 insertions, and L74V mutation are associated to profile #1, whereas the Q151M complex and M184V mutation are associated to both profiles. As some NRTI resistance mutations were associated preferentially with profile #1, further studies are needed to explore if, the weaker efficacy observed on viruses harbouring this profile using some NRTIs, could be explained by the TAMs profile itself or the other associated NRTI resistance mutations. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14635026     DOI: 10.1002/jmv.10550

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  49 in total

1.  Impact of HIV type 1 subtype on drug resistance mutations in Nigerian patients failing first-line therapy.

Authors:  B Chaplin; G Eisen; J Idoko; D Onwujekwe; E Idigbe; I Adewole; W Gashau; S Meloni; A D Sarr; J L Sankalé; E Ekong; R L Murphy; P Kanki
Journal:  AIDS Res Hum Retroviruses       Date:  2010-10-21       Impact factor: 2.205

2.  Risk factors for selection of the L74I reverse transcriptase mutation in human immunodeficiency virus type 1-infected patients.

Authors:  Marc Wirden; Bénédicte Roquebert; Anne Derache; Anne Simon; Claudine Duvivier; Jade Ghosn; Stephanie Dominguez; Véronique Boutonnet; Zaina Ait-Arkoub; Christine Katlama; Vincent Calvez; Anne-Genevieve Marcelin
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

3.  Clinical relevance of substitutions in the connection subdomain and RNase H domain of HIV-1 reverse transcriptase from a cohort of antiretroviral treatment-naïve patients.

Authors:  Atsuko Hachiya; Kazuki Shimane; Stefan G Sarafianos; Eiichi N Kodama; Yasuko Sakagami; Fujie Negishi; Hirokazu Koizumi; Hiroyuki Gatanaga; Masao Matsuoka; Masafumi Takiguchi; Shinichi Oka
Journal:  Antiviral Res       Date:  2009-02-21       Impact factor: 5.970

4.  Replicative capacity differences of thymidine analog resistance mutations in subtype B and C human immunodeficiency virus type 1.

Authors:  Kimberly L Armstrong; Tun-Hou Lee; M Essex
Journal:  J Virol       Date:  2009-02-18       Impact factor: 5.103

Review 5.  HIV-1 drug resistance mutations: an updated framework for the second decade of HAART.

Authors:  Robert W Shafer; Jonathan M Schapiro
Journal:  AIDS Rev       Date:  2008 Apr-Jun       Impact factor: 2.500

6.  In vitro cross-resistance profile of nucleoside reverse transcriptase inhibitor (NRTI) BMS-986001 against known NRTI resistance mutations.

Authors:  Zhufang Li; Brian Terry; William Olds; Tricia Protack; Carol Deminie; Beatrice Minassian; Beata Nowicka-Sans; Yongnian Sun; Ira Dicker; Carey Hwang; Max Lataillade; George J Hanna; Mark Krystal
Journal:  Antimicrob Agents Chemother       Date:  2013-08-26       Impact factor: 5.191

7.  Mutations in the connection domain of HIV-1 reverse transcriptase increase 3'-azido-3'-deoxythymidine resistance.

Authors:  Galina N Nikolenko; Krista A Delviks-Frankenberry; Sarah Palmer; Frank Maldarelli; Matthew J Fivash; John M Coffin; Vinay K Pathak
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-19       Impact factor: 11.205

8.  Synthesis and antiviral evaluation of 2-amino-6-carbamoylpurine dioxolane nucleoside derivatives and their phosphoramidates prodrugs.

Authors:  Jong Hyun Cho; Lavanya Bondana; Mervi A Detorio; Cathy Montero; Leda C Bassit; Franck Amblard; Steven J Coats; Raymond F Schinazi
Journal:  Bioorg Med Chem       Date:  2014-10-13       Impact factor: 3.641

9.  Prevalence and clinical significance of HIV drug resistance mutations by ultra-deep sequencing in antiretroviral-naïve subjects in the CASTLE study.

Authors:  Max Lataillade; Jennifer Chiarella; Rong Yang; Steven Schnittman; Victoria Wirtz; Jonathan Uy; Daniel Seekins; Mark Krystal; Marco Mancini; Donnie McGrath; Birgitte Simen; Michael Egholm; Michael Kozal
Journal:  PLoS One       Date:  2010-06-03       Impact factor: 3.240

10.  The "Connection" Between HIV Drug Resistance and RNase H.

Authors:  Krista A Delviks-Frankenberry; Galina N Nikolenko; Vinay K Pathak
Journal:  Viruses       Date:  2010-07-01       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.